emstoPA ^Company

Antidote to address possible intracranial bleeding during ischaemic stroke. The availability of a novel tPA-neutralising antidote to address possible intracranial bleeding caused by tPA, the current gold standard treatment for Ischemic Stroke, has the potential to save lives and reduce disability in multiple patients worldwide.